Ecphora Capital Management Company

Managing Partner Deborah Hemingway, PhD, leads investment decisions. She is a biophysicist by training and operates as a solo general partner. An extended team of venture partners and a managing director for operations support sourcing, diligence, and portfolio management.

Ecphora relies on exclusive institutional partnerships in the BioHealth Capital Region. It holds first-look access through The LaunchPort medical device accelerator and maintains structured relationships with Johns Hopkins University, the University of Maryland system, the NIH, and NIST. This funnel gives the firm early visibility into medtech innovations emerging from federally funded and academic laboratories.

Ecphora makes direct early-stage investments in medtech startups. It also operates SPV Concierge Services, which structures and administers special-purpose vehicles for portfolio companies and external syndicates, but the firm itself deploys capital through its own direct investment vehicle.

The firm's SPV Concierge operation suggests it is comfortable syndicating deals with other investors. However, Ecphora's public materials do not detail a formal co-investment program. Its primary posture appears to be leading or co-leading early-stage medtech rounds in the Mid-Atlantic ecosystem.

Ecphora's stated focus is exclusively medical: medical devices, biotech, digital health, and healthtech. It does not target enterprise software, fintech, consumer, or industrials, and its public positioning implies no intention to branch outside life sciences.